As a Texas NuvaRing lawyer, I am following the developments in the litigation of this medical device. NuvaRing is a non-biodegradable, flexible, latex-free vaginal ring which has a combination of the hormones estrogen and progestin. Etonogestrel, the active metabolite of desogestrel, is a synthetic form of the naturally occurring (female) sex hormone progesterone.
The NuvaRing vaginal contraceptive ring was originally developed by Organon, which is a Dutch pharmaceutical company. Organon received approval from the United States Food and Drug Administration to sell NuvaRing device in the United States on October 3, 2001. Interestingly, in October 2003, The New England Journal of Medicine addressed research indicating that desogestrel, when taken orally, can significantly increase a person’s risk of blood clots. However, by 2007, approximately 1,500,000 women were NuvaRing around the world. In June 2010, a Swiss report was released which indicated that there were about 40 deaths reported in the United States FDA database of adverse events associated with the Nuvaring device.
Schering-Plough purchased Organon in 2007. Schering-Plough then merged with Merck in 2009. According to the makers of the medical device, NuvaRing is up to 99% effective in preventing pregnancy when used properly. However, NuvaRing may cause a range of rare and extremely severe side effects. Nuvaring can even cause a woman’s death. Many lawsuits have been filed against Merck because of these severe and dangerous side effects.
Some of the severe side effects of NuvaRing use include:
•Deep vein thrombosis
•Heart attack, stroke and/or pulmonary embolism
•Liver tumors, and